Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Predicted Market Size Of The Neurotrophic Keratitis Treatment Industry By 2029?

The scale of the market for treatment of neurotrophic keratitis has seen significant escalation lately. The predicted growth is from $1.08 billion in 2024 to $1.47 billion in 2025, representing a compound annual growth rate (CAGR) of 36.3%. The substantial growth during previous years can be ascribed to factors such as growing number of diagnoses, escalating incidents of injuries and surgical procedures, enhanced research and development, as well as improvement in global healthcare infrastructure.

The market for neurotrophic keratitis treatment is expected to witness extraordinary growth in the next several years, expanding to $4.99 billion by 2029, with a compound annual growth rate (CAGR) of 35.9%. The anticipated surge during the forecast period is credited to educational endeavors, a rise in clinical trials, development of sophisticated therapies, along with regulatory sanctions. The forecast era is also expected to bring about significant trends like enhancement in diagnostic tools, implementation of digital health solutions, the advent of neuroprotection strategies, and the improvement of advanced ocular surface imaging.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12968&type=smp

Which Factors Are Steering Growth In The Neurotrophic Keratitis Treatment Market?

The neurotrophic keratitis treatment market’s growth is seen to be driven by the escalating incidence of eye ailments. These include various medical complications and disorders that negatively impact the eyes’ structure and functionality. Aiding in the enhancement of corneal sensation, fostering healing, forestalling infection, and alleviating pain and discomfort are possible benefits of neurotrophic keratitis treatment. As reported by Eye Care One, an American career development services platform specialising in eyecare, in March 2022, it’s projected that the number of US citizens afflicted with dry eye disease (DED) will reach 35 million in 2022, with annual increases anticipated. Furthermore, according to a May 2024 report by the Centers for Disease Control and Prevention, a federal agency under the Department of Health and Human Services based in the US, over 3.4 million American individuals aged 40 and above suffer from blindness or visual impairment, a figure expected to double by 2030. Hence, the surging incidence rate of eye maladies is fuelling the expansion of the neurotrophic keratitis treatment market.

Which Segment Accounts For The Largest Share In The Neurotrophic Keratitis Treatment Market?

The neurotrophic keratitis treatmentmarket covered in this report is segmented –

1) By Treatment: Topical Antibiotics; Recombinant Human Nerve Growth Factor (rhNGF); Amniotic Membrane Transplantation; Keratoplasty; Other Treatments

2) By Route of Administration: Oral; Topical; Other Routes of Administration

3) By Application: Stage I; Stage II; Stage III

4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users

Subsegments:

1) By Topical Antibiotics: Broad-Spectrum Antibiotics; Narrow-Spectrum Antibiotics

2) By Recombinant Human Nerve Growth Factor (rhNGF): Cenegermin Ophthalmic Solution; Other rhNGF-Based Solutions

3) By Amniotic Membrane Transplantation: Cryopreserved Amniotic Membrane; Dehydrated Amniotic Membrane

4) By Keratoplasty: Penetrating Keratoplasty; Lamellar Keratoplasty

5) By Other Treatments: Tarsorrhaphy; Therapeutic Contact Lenses

Which Disruptive Trends Are Driving Change Across The Neurotrophic Keratitis Treatment Market?

Major firms in the neurotrophic keratitis treatment market are investing in the creation and approval of innovative medications to maintain their market standing. With current treatments being limited and the pressing need for more potent therapies to halt the advancement of the disease, drug development is a critical aspect of neurotrophic keratitis treatment. For example, in December 2022, BRIM Biotechnology Inc., a clinical-stage company headquartered in Taiwan, was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for its BRM424 drug for neurotrophic keratitis (NK) treatment. BRM424, a recombinant type of human nerve growth factor, promotes the growth and diversification of corneal limbal stem cells, aiding in the rejuvenation of the corneal health of neurotrophic keratitis patients.

Who Are The Dominant Players In The Neurotrophic Keratitis Treatment Market Today?

Major companies operating in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Grand Pharma Co. Ltd., Walgreen Co., Pfizer Inc., Johnson and Johnson, Bayer AG, Novartis AG, Abbott Laboratories, Gilead Biosciences Inc., Merck and Co. Inc., Allergan Inc., Alcon Inc., Bausch Health Companies Inc., Bausch & Lomb Inc., CooperVision Inc., Rohto Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Zhejiang Conba Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc., Laboratoires Thea SAS, Leadiant Biosciences Inc., ReGenTree LLC, Contacare Opthalmic Private Limited, Neuroptika Inc., Surgitech Innovation Private Limited.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report

What Regional Factors Are Accelerating Growth In The Neurotrophic Keratitis Treatment Market?

North America was the largest region in the neurotrophic keratitis treatment market in 2024. The regions covered in neurotrophic keratitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12968&type=smp

Browse Through More Reports Similar to the Global Neurotrophic Keratitis Treatment Market 2025, By The Business Research Company

Dry Eye Medication Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dry-eye-medication-global-market-report

Newborn Eye Imaging Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/newborn-eye-imaging-systems-global-market-report

Dry Eye Syndrome Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dry-eye-syndrome-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model